New study suggests alcohol may weaken cancer immunotherapy

18.11.2026 - A new study published on 17 November 2026 in Science Signaling suggests that regular alcohol consumption may reduce the effectiveness of certain cancer immunotherapies by interfering with the immune cells responsible for attacking tumours. The findings provide new insights into how alcohol may affect cancer treatment, beyond its established role as a cause of cancer.
Researchers led by Kristen Gilley at the University of North Carolina at Chapel Hill investigated the effects of alcohol on immune checkpoint inhibitors, a type of cancer treatment that helps the immune system recognise and attack cancer cells. The study combined experiments involving mice with lung and bladder cancer with an analysis of patient treatment records.
Alcohol reduced treatment effectiveness in mice
In the animal experiments, researchers administered alcohol at levels estimated to correspond to approximately three to six drinks per day in humans. Alcohol exposure reduced the effectiveness of immunotherapy by roughly 50% and increased the likelihood of tumour recurrence.
The researchers identified several changes in the immune system that could explain these findings. Alcohol reduced the number of T cells entering tumours and disrupted the activity of memory T cells, which help the immune system recognise and respond to cancer cells.
At the same time, alcohol increased the proportion of T cells expressing TIGIT, a receptor that can suppress immune responses. When researchers blocked this receptor using antibodies, the effectiveness of anti-PD-1 immunotherapy improved in the mice.
This suggests a possible biological mechanism through which alcohol interferes with cancer treatment and identifies potential targets for further research.
Patient data point to similar concerns
The researchers also examined existing records from patients receiving immunotherapy for lung, bladder, skin, and head and neck cancers.
Regular alcohol consumption, including reports of eight or more drinks per week, was associated with poorer survival following treatment. The clearest evidence concerned patients with lung cancer, while the available information for other cancer types was insufficient to establish firm conclusions.
Importantly, the patient analysis was retrospective. It identified an association between alcohol consumption and treatment outcomes but cannot establish that alcohol directly caused the poorer survival rates.
Implications for cancer treatment
The findings raise an important question about alcohol's effects on cancer care. While alcohol is already recognised as a cause of several types of cancer, its potential influence on the effectiveness of cancer treatments has received considerably less attention.
The researchers emphasise that further clinical studies are needed to establish how alcohol consumption affects immunotherapy outcomes in patients and whether reducing alcohol consumption could improve treatment responses.
They also recommend systematically recording alcohol consumption in cancer treatment databases to better understand its potential effects across different cancers and therapies.
Source: Gilley, K. N. et al. (2026). Alcohol use reduces the efficacy of anti-PD1 immunotherapy by disrupting antitumor immunity. Science Signaling, 19, eaef1375. Published 17 November 2026. DOI: 10.1126/scisignal.aef1375. AAAS/EurekAlert news release, 17 November 2026.
Full article: Science Signaling




Comments